PAVE
EU-Consotrium PAVE “A nanovaccine Approach for the treatment of Pancreatic Cancer” (H2020-MSCA-ITN-2019)
Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers, which are currently the 4th leading cause of cancer-related death and predicted to become the 2nd leading cause. PDAC is aggressive, invasive, rapidly metastatic and resistant to most chemo- or radiotherapies. The outlook for most patients is very poor because the disease is usually only identified when well advanced.
The basic concept of PAVE is to establish new strategies and approaches for cancer vaccines as a primary objective, in conjunction with modulation of the tumour microenvironment (TME), in the treatment of pancreatic ductal adenocarcinoma (PDAC).
Transitional animal models serve a crucial role in bridging the gap between fundamental diagnostic and therapeutic discoveries and human clinical trials. The development of therapeutic cancer vaccines has been largely studied on mice. Recent findings have shown the pig immunome to be much more similar to the human counterpart. Our objective for this project is generation of an oncopig PDAC model as a next-generation large animal platform for human cancer vaccine development.
Find more information on the PAVE website: www.pave-cancer.eu or in the flyer.